Follistatin domain containing proteins
View Patent ↗The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.
1. A method of treating a patient suffering from a muscle disorder associated with GDF-8, comprising administering to the patient in need thereof a therapeutically effective dose of a protein comprising at least one follistatin domain, wherein the protein is follistatin related gene (FLRG), and thereby improving a GDF-8 related biological outcome in the patient, wherein the biological outcome is chosen from an increase in muscle mass, an increase in muscle strength, decreased adiposity, and improved glucose homeostasis, thereby treating the patient suffering from a muscle disorder.
2. The method of claim 1 , wherein the muscular disorder is muscular dystrophy.
3. The method of claim 2 , wherein the muscular dystrophy is chosen from severe or benign X-linked muscular dystrophy, limb-girdle dystrophy, facioscapulohumeral dystrophy, myotonic dystrophy, distal muscular dystrophy, progressive dystrophic ophthalmoplegia, oculopharyngeal dystrophy, and Fakuyama-type congenital muscular dystrophy.
4. A method of inhibiting or reducing a GDF-8 activity to achieve a desired biological outcome, comDrising administering to a mammal at least one protein comprising at least one follistatin domain, wherein the protein is FLRG, and wherein the protein inhibits a GDF-8 activity, thereby inhibiting or reducing the GDF-8 activity and improving a GDF-8 related biological outcome in the mammal, wherein the biological outcome is chosen from an increase in muscle mass, an increase in muscle strength, decreased adiposity, and improved alucose homeostasis.